Insider Purchases: Inside the Buy

Tag: hub-overseas

Illustration of an antibody molecule breaking through a descending stock chart, symbolizing AbCellera’s biotech turnaround and short squeeze potential.

AbCellera (ABCL) Stock Analysis: 7 Triggers for a Biotech Short Squeeze or Long-Term Multibagger?

Down 95%, heavily shorted, yet sitting on $700M in liquidity and insider conviction — AbCellera (ABCL) may be biotech’s ultimate asymmetric bet.

Read entire article

Tags: AbCellera Biologics, ABCL, AndrewBoothCFO, Baker Bros, Biotech Stocks, BuyOrSellABCL, CFO Andrew Booth, Clinical Trials, featured-overseas, FUNanc1al Edge, FUNanc1al Investing, FunStock Index, High Risk Investing, hub-hedge, hub-insiders, hub-overseas, Insider Buying, John Montalbano, RisksBuyingABCL, Short Squeeze, Small Cap Stocks, WhyBuyABCL
Illustration showing advanced cancer diagnostics and DNA science balanced against financial risk, representing Mainz Biomed’s promising technology and high-risk biotech investment profile.

Insider Buys Shares of Mainz Biomed: Promising Science, Precarious Finances

Mainz Biomed’s cancer-screening science is compelling — and an insider just bought big. But with heavy losses, dilution risk, and a going-concern warning, MYNZ is a biotech moonshot best approached with extreme caution.

Read entire article

Tags: 10% owner buying, Biotech Stocks, buy or sell MYNZ, Colorectal Cancer, Early Cancer Detection, featured-insiders, funanc1al edge, funanc1al humor, funanc1al investing, FUNstock Index, Going Concern, High Risk High Reward, hub-insiders, hub-overseas, Insider Buying, Mainz Biomed, Microcap Biotech, MYNZ, Pancreatic Cancer, risks buying mynz, Speculative Stocks, why buy mynz
Illustration of a stylized crown hovering above biotech molecules and financial charts, representing XOMA Royalty’s strategy of collecting biotech royalties without developing drugs.

Can XOMA Become Royalty? The CEO, BVF Partners, and Morgan Stanley Think So!

XOMA Royalty doesn’t run clinical trials—it collects royalties. With a $2.5M CEO insider buy, heavyweight institutional backing, and improving cash flow, this biotech quiet achiever may be turning into something… royal.

Read entire article

Tags: Biotech Royalties, Biotech Stocks, buy-or-sell-XOMA, CEO buy, CEO Buys, CEO Conviction, CEO insider buying, CEO Insider Purchases, CEO Stock Purchase, CEOBuyIn, CEOConfidence, featured-insiders, funanc1al edge, funanc1al humor, FUNanc1al Investing, FUNstock Income + Growth, Healthcare Investing, hub-diversify, hub-epiphany, hub-fun, hub-hedge, hub-insiders, hub-ipos, hub-overseas, hub-ridiculous, hub-special-files, hub-value, Insider Buying, risks-investing-in-xoma, Royalty Stocks, Small-Cap Stocks, why-buy-xoma, XOMA, XOMA Royalty
Playful illustration of a Lyft car sprouting wings, symbolizing stock lift-off potential against bigger Uber competition.

Lyft’s CEO Keeps Buying Shares. Are They About to Lift Off?

Lyft’s CEO keeps buying stock while hedge funds pile in. With profits, free cash flow, and share buybacks, could LYFT finally lift off—or hit roadblocks? 🚗📈

Read entire article

Tags: Autonomous Vehicles, CEO Buys, CEO Conviction, CEO insider buying, CEO Stock Purchase, CEOBuyIn, CEOConfidence, Free Cash Flow, Funanc1al, FUNanc1al Edge, Funanc1al humor, FUNanc1al Investing, Growth Stocks, Hedge Fund Moves, hub-overseas, Insider Buying, Is Lyft a Buy, John David Risher, Lyft Stock, Rideshare Stocks, Transportation Tech, Uber vs Lyft